ODTX

Odyssey Therapeutics Inc

19.53

Nov 02 • 3:59 PM ET -0.01 (-0.05%)

19.53

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: ALMS ABVX ZBIO ATTO JBIO MLTX SYRE ANAB ORKA EVMN

| Held by: VTI IWM VXF VTWO IWO SCHA IWN IWC SCHB VTWG

Scroll to Statements

Index	RUT
Market Cap	938.58M
Enterprise Value	652.83M
Income	-
Sales	-
Book/sh	8.80
Cash/sh	6.46
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	May 08, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.22
P/C	3.02
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.36
Current Ratio	11.36
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-4.77
EPS next Q	-1.09
EPS this Y	-15.42%
EPS next Y	19.90%
EPS next 5Y	3.98%
EPS past 3/5Y	-6.04% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-41.16%
Sales Q/Q	-100.00%
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	59.13%
Insider Trans	17.26%
Inst Own	31.46%
Inst Trans	70.92%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.95%
SMA50	-9.81%
SMA200	-0.93%
Trades

Shs Outstand	47.89M
Shs Float	19.64M
Short Float	16.71%
Short Ratio	12.59
Short Interest	3.28M
52W High	29.05 -32.77%
52W Low	15.10 29.34%
Volatility	7.57% 7.77%
ATR (14)	1.55
RSI (14)	48.88
Beta	-
Rel Volume	0.99
Avg Volume	260.61K
Volume	258,945

Perf Week	1.19%
Perf Month	-5.77%
Perf Quarter	-2.15%
Perf Half Y	-
Perf YTD	-2.35%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.12
Target Price	35.33
Prev Close	19.54
Price	19.53
Change %	-0.05%

Consensus

Strong Buy

Avg. Price Target

$35.33

Implied Upside

+80.9%

Analysts8incl. previous ratings

Rating Distribution8 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Initiated	UUBS	Buy	$27	+38.2%
Oct 09, 2026	Initiated	RRaymond James	Outperform	$42	+115.1%
Aug 27, 2026	Initiated	HH.C. Wainwright	Buy	$44	+125.3%
Jun 02, 2026	Initiated	WWedbush	Outperform	$30	+53.6%
Jun 02, 2026	Initiated	TTD Cowen	Buy
Jun 02, 2026	Initiated	OOppenheimer	Outperform	$40	+104.8%
Jun 02, 2026	Initiated	JJP Morgan	Overweight	$26	+33.1%
Jun 02, 2026	Initiated	CCantor Fitzgerald	Overweight

Oct-20-26 07:00AM	Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026 (GlobeNewswire)
Oct-12-26 08:00AM	Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026 (GlobeNewswire)
Oct-06-26 08:00AM	Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026 (GlobeNewswire) -13.00%
Sep-16-26 08:00AM	Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire) +5.14%
Aug-26-26 08:00AM	Odyssey Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
06:10AM	Loading…
Aug-07-26 06:10AM	Evotec and Odyssey collaborate on AI-enabled R&D (Pharmaceutical Technology)
Aug-06-26 06:32AM	Odyssey Therapeutics: Q2 Earnings Snapshot (Associated Press)
Aug-04-26 07:00AM	Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +10.09%
Jun-18-26 12:56PM	Kardigan rises in Nasdaq debut after upsized $400 million IPO (Reuters)
Jun-17-26 04:51PM	Odyssey Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:15PM	Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-26 08:31AM	Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip (GuruFocus.com) +6.27%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TPG GP A, LLC	Former 10% Owner	May 11 '26	Buy	18.00	1,388,889	25,000,002	3,690,146	May 13 05:10 PM
Dimension Capital II, L.P.	Director	May 08 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 12 05:37 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Buy	18.00	555,555	9,999,990	1,831,383	May 11 09:11 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Sale	18.00	1,780	32,040	440,981	May 11 09:11 PM
LEIDEN JEFFREY M	Director	May 08 '26	Buy	20.00	5,000	100,000	270,198	May 11 08:35 PM
Haas Jason	Chief Financial Officer	May 08 '26	Buy	20.00	1,000	20,000	62,908	May 11 08:32 PM
Li Nan (LN)	Director	May 11 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 11 08:30 PM
Chu Shelley	Director	May 11 '26	Buy	18.00	11,111	199,998	11,111	May 11 08:30 PM

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

FounderDr. Gary D. Glick Ph.D.

Chief Financial OfficerMr. Jason Haas M.B.A.

Senior Vice President of Strategy & Business DevelopmentMr. Collin Todd

Ph.D.Prof. Eicke Latz M.D.

Scientific Co-FounderDr. Kim Lewis Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ODTX

Odyssey Therapeutics Inc

Upgrade your Finviz experience